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Abstract 
Lutein and zeaxanthin, two carotenoid pigments of the xanthophyll subclass, are present in high concentrations in 
the retina, especially in the macula. They work as a filter protecting the macula from blue light and also as a resident 
antioxidant and free radical scavenger to reduce oxidative stress-induced damage. Many observational and inter-
ventional studies have suggested that lutein and zeaxanthin may reduce the risk of various eye diseases, especially 
late forms of AMD. In vitro and in vivo studies indicate that they could protect various ocular cells against oxidative 
damage. Recent research has shown that in addition to traditional mechanisms, lutein and zeaxanthin can influence 
the viability and function of cells through various signal pathways or transcription factors: for instance, they can affect 
immune responses and inflammation, and have anti-angiogenic and anti-tumor properties. This review covers the 
basic aspects and results of recent studies regarding the effects of lutein, zeaxanthin and other carotenoids, such as 
meso-zeaxanthin, on the eye in different clinical and experimental models and the management of various ocular 
diseases using these molecules.
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provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, 
and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/
publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
Background
The central portion of the retina or macula is responsi-
ble for optimal spatial vision [1]. Macular pigment (MP) 
is a generic term used to describe the yellow pigment 
composed principally of the three isomeric carotenoids 
meso-zeaxanthin (MZ), lutein (L), and zeaxanthin (Z), 
which accumulate in the macula [2, 3] (Fig. 1). The high-
est levels of MP in the human body are measured in Hen-
le’s fibers at the fovea and in the inner nuclear layer in the 
parafoveal area [4–6]. MP acts as an optical filter for blue 
light and provides antioxidant protection to the human 
retina by inhibiting the peroxidation of long-chain poly-
unsaturated fatty acids [7–9]. Thus, the anatomical [2], 
biochemical [8], and optical [7] properties of MP have 
generated interest in its role in vision and macular health.
There is increasing evidence that MP is important for 
vision in normal subjects [10, 11], based upon MP’s abil-
ity to optimize visual performance and experience by 
attenuating chromatic aberration, veiling luminance, 
and blue haze [12]. Moreover, it has generated interest 
because of its possible protective role against age-related 
macular degeneration (AMD), the western world’s lead-
ing cause of irreversible blindness [13]. Since oxidative 
damage seems to be an important factor for the develop-
ment and exacerbation of some retinal diseases [14, 15], 
the postulated protective role of MP in some disorders, 
especially AMD, has been extensively investigated over 
the past decades [16, 17].
Anatomical, chemical and optical properties of MP 
related to their biofunctions in the eye
Macular pigment concentration peaks at the foveola. L is 
the dominant carotenoid in the peripheral macula, Z in 
the mid-peripheral macula, and MZ at the epicenter of 
the macula [2, 5, 6]. The term macula lutea (yellow spot) 
is actually attributable to the presence of these carote-
noids in the central region of the retina [12]. The L:Z ratio 
in the fovea is approximately 1:2.4. Moving eccentrically 
to the periphery, Z levels decline while L levels increase. 
Therefore, L:Z in the peripheral macula reverses, exceed-
ing 2:1 [18]. Bone et al. demonstrated that Z coexists with 
its isomer MZ in the fovea. They also proposed that L, 
MZ, and Z are actually found in equal quantities in the 
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central macula (area 3 mm in diameter within the central 
macula) [19]. MZ, unlike L and Z, was previously thought 
to be undetectable in the human liver or serum. Thus, 
it was theorized that MZ was a specific metabolite of L 
found only in the retina. The L:Z of 3:1 in serum and 2:1 
in the fovea support the theory of conversion of L to MZ 
in the macula [2]. However, more recently, MZ has been 
detected in serum, and supplementation trials have dem-
onstrated a significant increase in macular pigment levels 
after oral administration of MZ, suggesting that MZ can 
be absorbed after oral intake and transported to the mac-
ula [20–22]. In addition, the augmentation of macular 
pigment was higher after oral administration of formulas 
containing MZ [22].
Carotenoids are often referred to as pigments or 
chromophores because of their mostly colored nature 
and consequential ability to absorb visible light. All 
carotenoids have a characteristic linear conjugated poly-
ene chain and are classed into one of two subgroups. The 
hydrocarbon carotenoids are known as carotenes, such 
as β-carotene and lycopene, whereas carotenoids that 
are substituted with hydroxyl (–OH) functional groups 
are known as xanthophylls and include L, Z and MZ 
[23]. The hydroxyl functional groups permit L, Z and 
their structural isomers to cross the blood–ocular and 
blood–brain barriers. Other carotenoids (β-carotene and 
lycopene) contain only carbon and hydrogen atoms and 
do not cross the blood–brain or ocular barriers [24, 25]. 
β-carotene only crosses the blood brain barrier after it is 
cleaved to form retinaldehyde and other metabolites [26]. 
L and Z share the carbon skeleton and bonding frame-
work of a- and b-carotene, respectively. The bonding 
frameworks of these two carotenoids may appear identi-
cal, at first glance. The chemical formulas of L and Z are 
chemically distinguished from one another in important 
ways (Fig. 2). Z exists in three stereoisomeric forms, the 
result of the two stereocenters at carbons 3 and 3′, the 
sites of the secondary hydroxyl groups. L can exist in 
eight stereoisomeric forms as a result of the presence of 
three stereocenters at the 3, 3′, and 6′ carbon atoms. In 
addition, the hydroxyl group at carbon 3′ of L is allylic 
[3]. Z and MZ are classified as diastereomers and differ 
only in the spatial orientation of the hydroxyl group on 
the C3′ chiral position. The structural differences of MZ, 
L, and Z have important implications for their respective 
antioxidant and light-filtering properties [23, 27].
The absorption spectra of MP peak at 460 nm [28, 29]. 
Although MZ, L, and Z exhibit very similar absorption 
spectra, it is possible to distinguish them on the basis 
of discrete variations in relative absorbance (nm) and 
intensity (AU) [3]. Because of their chemical structure, 
these carotenoids together are responsible for blue-light 
absorption and quenching of reactive oxygen species 
(ROS), thus attenuating oxidative injury at the macula 
[23, 30, 31]. Although Z and MZ are more efficient than 
L at eliminating ROS, a mixture of L, Z, and MZ in vitro, 
at a ratio of 1:1:1, has been shown to quench more singlet 
oxygen than any of these individual carotenoids at the 
same total concentration [32–34]. Macular carotenoids 
are very effective antioxidants, capable of quenching sin-
glet oxygen and triplet state photosensitizers, inhibiting 
peroxidation of membrane phospholipids, scavenging 
ROS, and reducing lipofuscin formation [35, 36]. These 
essential functions of macular pigment decrease oxida-
tive stress in the retina and enhance vision in both nor-
mal and abnormal retinas.
Macular pigment and visual performance
Macular pigment enhances visual function in a variety of 
ways. The filtration of blue light (400–500  nm) reduces 
chromatic aberration, which can enhance visual acu-
ity and contrast sensitivity (CS) (Fig.  3). L and Z also 
Fig. 1 Autopsy specimen of the macula lutea or “yellow spot”
Fig. 2 Biochemical structures of the main carotenoids of macular 
pigment
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reduce discomfort associated with glare and improve 
photostress recovery time, macular function, and neu-
ral processing speed. Discomfort glare is a term used to 
describe photophobia and discomfort experienced when 
intense light enters the eye. Stringham et al. analyzed the 
photophobic response in normal subjects and found that 
those with higher MP levels tolerated xenon light better. 
They concluded that light containing short-wavelength 
energy appeared to be especially discomforting and that 
MP appeared to act as a spatially integrated filter, serving 
to attenuate photophobia to a great extent [37]. Similarly, 
Wenzel et  al. showed a direct correlation between MP 
level and photophobia threshold [38].
Disability glare is a term used to describe decreased 
visual acuity resulting from scattered light, another phe-
nomenon that results from bright light settings. Pho-
tostress recovery is described as the time necessary 
to recover vision following exposure to a bright light 
source. Physiologically, it represents the time necessary 
for photopigments bleached by a bright light source to 
regenerate. A study conducted by Stringham and Ham-
mond [39] demonstrated that subjects with higher MP 
levels maintained better visual acuity than subjects with 
lower levels when exposed to both bright white light and 
short wavelength (blue) light. Additionally, photostress 
recovery time, after exposure to xenon-white light, was 
significantly shorter for subjects with higher MP lev-
els. A more recent study showed that higher MP optical 
densities (MPODs) resulted in faster photostress recov-
ery times, lower disability glare contrast thresholds, and 
lower visual discomfort [40]. Hammond et  al. reported 
that daily oral supplementation with L (10 mg/day) and Z 
(2 mg/day) in 57 patients for 12 months resulted in a sig-
nificant increase in serum levels of L and Z and in MPOD 
and significantly improved chromatic contrast and pho-
tostress recovery time [41]. These results were consistent 
with past studies showing that increasing MPOD leads to 
improved visual performance.
Nolan et  al. performed a randomized, placebo-con-
trolled clinical trial supplementing healthy and young 
subjects with lutein and zeaxanthin for 12  months [42]. 
The goal was to identify if different parameters of visual 
performance could be improved after supplementation 
in a population with relatively high macular pigment lev-
els who are considered to be at peak visual performance. 
The authors did not show a significant change in visual 
performance in supplemented patients despite increas-
ing serum L levels and central macular pigment levels. 
However, they did demonstrate significant differences 
in mesopic CS and light/dark adaptation in a compara-
tive analysis between the lower and the upper MP tertile 
groups. These findings suggest that subjects with low MP 
levels and suboptimal visual performance may benefit 
more from supplementation.
Interestingly, several studies have reported, among nor-
mal subjects, findings suggesting that MP may play a key 
role in visual health through a complex interplay between 
the optical, neurological and physiological mechanisms 
underlying vision. These observations include a better 
critical flicker fusion frequency in the presence of higher 
MPOD [43], associations between high MPOD and crys-
talline lens transparency and cataract formation [44], 
the presence of L and Z at substantial concentrations in 
the primary visual cortex, [45] and higher pattern elec-
troretinogram P50 amplitudes and better dark adapted 
cone sensitivities in association with higher MPOD [46]. 
Additionally, MPOD correlates with processing speed 
and cognitive performance in healthy elderly subjects as 
well as those with mild cognitive impairment [47–49]. 
Another study found moderate but statistically signifi-
cant improvements in both MPOD and visual processing 
speed when supplementing young and healthy individu-
als considered to be at peak cognitive efficiency [50].
Clinical measurement of MP
Several objective techniques have been used to meas-
ure MPOD indirectly and noninvasively in  vivo. They 
are divided into either psychophysical (heterochromatic 
flicker photometry, HFP [51] and motion photometry 
[52]) or optical methods (autofluorescence spectrometry 
[53], reflectometry [54], imaging reflectometry [55] and 
Raman spectrometry [56]). They have been previously 
well described in the literature and each one has certain 
merits and limitations. In conjunction with many of the 
MPOD techniques, HFP is based on the spectral absorp-
tion properties and retinal location of MP. Essentially, 
HFP determines MPOD by presenting a light stimu-
lus of two alternating wavelengths at the fovea and at a 
Fig. 3 Differential absorption of blue light shows MP location in the 
Henle fiber layer and inner plexiform layer along the axons of the 
photoreceptors
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parafoveal area, one that is short and maximally absorbed 
by MP, and another longer and not absorbed by MP [57]. 
This method has evolved during the past decades and 
it has been used in different study and clinical popula-
tions. Its main disadvantage is the difficulty to perform in 
young patients, people with insufficient visual acuity or 
visual fields, or with low cognitive tasks.
The autofluorescence method is based on the principle 
of autofluorescence of lipofuscin, which is located in the 
retinal pigment epithelium cells. This is one of the more 
recently introduced methods and allows objective and 
reliable measurements of MP distribution in the retina 
and is particularly easy to implement in a clinical prac-
tice [58–61]. Quantitative measurement of light reflected 
from the fundus is known as fundus reflectometry and 
its main goal is compare light reflected at the macula and 
light reflected from a peripheral area of the retina. Cur-
rently, HFP and retinal reflectometry are the most widely 
used techniques for MPOD measurement in the research 
and clinical environments, respectively [57].
Clinical effects of supplementation of lutein 
and zeaxanthin in patients with AMD
AMD is a chronic, progressive, degenerative eye disease 
affecting the central retina, responsible for highest visual 
acuity. It has become the major cause of legal blindness in 
the elderly, in both developed and developing countries 
[62–64]. It has been shown that oxidative stress related to 
low-grade inflammation and hypoxia in the outer retina 
are important in the pathogenesis of AMD [62]. This is 
consistent with the idea that low MPOD may be a risk 
factor for AMD, because the macular carotenoids show 
potent properties as antioxidants [9, 65].
Indeed, many large observational studies have shown 
an inverse relationship between dietary intake of L and Z 
and risk of AMD [66, 67]. A systematic review and meta-
analysis on this matter analyzed six longitudinal cohort 
studies and found that early and late AMD have differ-
ent relationships with the intake of L and Z [68]. Dietary 
intake of these carotenoids was significantly related to 
a reduction in risk of late AMD (RR 0.74; 95 % CI 0.57, 
0.97), and a statistically significant inverse associa-
tion was observed between L/Z intake and neovascular 
AMD risk (RR 0.68; 95  % CI 0.51, 0.92). No significant 
relationship was found for dietary intake of these carot-
enoids and early AMD. In the Age-Related Eye Disease 
Study (AREDS) Report 22, the relationship between 
dietary intake of L/Z and late AMD was evaluated in 
4519 patients. Dietary L/Z intake was inversely associ-
ated with neovascular AMD [odds ratio (OR) 0.65; 95 % 
CI 0.45–0.93], geographic atrophy (OR 0.45; 95  % CI 
0.24–0.86), and large or extensive intermediate drusen 
(OR 0.73; 95  % CI 0.56–0.96), comparing the highest 
vs lowest quintiles of intake, after adjustment for total 
energy intake and nonnutrient-based covariates. Other 
nutrients (β-carotene, vitamin C, vitamin E, lycopene, 
etc.) were not independently related to AMD [16]. Fur-
thermore, participants from the Rotterdam Study were 
enrolled into a case–control study investigating whether 
dietary nutrients could reduce the genetic risk of early 
AMD. Participants from a large population-based cohort 
at risk of AMD were followed for a mean of 8.6  years. 
They reported that high dietary intake of nutrients with 
antioxidant properties such as L and Z, β-carotene, 
omega-3 fatty acids, and zinc reduced the risk of early 
AMD in those at high genetic risk [69].
The first report that analyzed the association between 
MP density in the human retina and risk for AMD was 
published by Bone et  al. [70]. It had demonstrated that 
retinas from donors with AMD showed significantly 
lower levels of MP compared to retinas without; and 
donors with the highest quartile of L/Z had an 82 % lower 
risk of having AMD compared to donors in the low-
est quartile. This was the first study to report decreased 
levels of MP density in patients with AMD, which cor-
related with previous studies analyzing diet and serum 
carotenoid levels. The authors did note that decreased 
MP could at least in part be attributable to the disease 
destructive process. Lower levels of MP have also been 
associated with increased age and other risk factors for 
AMD, including a positive family history of AMD and 
smoking [71].
Several interventional studies have suggested that 
visual function of AMD patients can be improved by L 
and/or Z supplementation [72, 73], but some have still 
failed to find such results [74]. Liu et  al. performed a 
meta-analysis comparing results of eight randomized, 
double-blind trials involving 1176 AMD patients in total, 
which compared L and/or Z intervention with placebo 
[75]. Four of seven studies demonstrated a significant 
improvement in visual acuity (VA) with supplementation. 
Moreover, patients supplemented with those xanthophyll 
carotenoids had significantly increased CS at all spatial 
frequencies compared with those who received placebo. 
The analysis demonstrated that oral supplementation is 
associated with significant improvements in VA and CS 
in a dose–response relationship. Also, a linear associa-
tion of MPOD and an increase in VA and CS at middle 
frequency was noted, which suggested that morphologi-
cal restoration of the macula might have been responsi-
ble for the observed effects of improved function. These 
results were in agreement with previous findings from 
the same group, who found significant morphological 
changes in MP at the central retina within 24 weeks, but 
no improvement in visual function until 48  weeks [76]. 
Similarly, the results of the TOZAL study also indicated 
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that AMD patients were likely to require supplemen-
tations for at least 6-months to obtain positive changes 
in VA outcomes [77]. Patients with late AMD com-
pared with early AMD tended to have a less significant 
improvement in VA, and this finding was attributed to 
the loss of macular photoreceptors in the late stage of the 
disease [75].
After the release of findings of smaller trials mentioned 
above, the Age-Related Eye Disease-2 Study (AREDS2) 
was published [17]. It was a multicenter, randomized, 
double-masked, placebo-controlled clinical trial follow-
ing 4203 participants with intermediate AMD or large 
drusen in 1 eye and advanced AMD in the fellow eye 
for approximately 5 years. Participants were assigned to 
placebo, L (10 mg) and Z (2 mg), omega 3 fatty acids, or 
the combination of L, Z, and omega 3 fatty acids. In addi-
tion they were administered either the original AREDS 
formulation or some modification of the original for-
mulation (eliminating β-carotene, lowering zinc dose, 
or a combination of the two). The original analysis did 
not find significant effects from the supplementation of 
these bioactive substances. However, a secondary analy-
sis of the effects of L/Z on AMD progression in AREDS 2 
revealed definitively positive results [78]. The authors re-
evaluated the results of AREDS2 by analyzing L/Z vs no 
L/Z, and comparing L/Z vs β-carotene. In the analysis of 
L/Z vs no L/Z, the development of late AMD was signifi-
cantly decreased in patients treated with L/Z. Analyses of 
the comparison of L/Z vs β-carotene also showed a sig-
nificant decrease in the risk of developing late AMD and 
neovascular AMD in the L/Z group, but did not appear 
to influence the development of geographic atrophy. In 
analyses restricted to eyes with bilateral large drusen at 
baseline, the comparison of L/Z vs β-carotene showed 
protective effects of MP with regard to progression to 
late AMD and neovascular AMD. The authors concluded 
that the totality of evidence regarding beneficial and 
adverse effects of β-carotene in AREDS2 and other stud-
ies suggests that L/Z is more appropriate than β-carotene 
for the new AREDS2 formulation. It is important to 
emphasize that unlike other carotenoids, β-carotene has 
a much broader distribution within the body that corre-
lates with the wide expression of the cleavage enzymes 
in various tissues. Also the mechanism of tissue uptake 
of β-carotene is not fully understood [26] and this may 
play a role on the absence of significant beneficial effects 
showed on AREDS 2.
Finally, recent trials showed positive results regard-
ing retinal function after treatment with macular carot-
enoids. Huang et  al. found significant improvements in 
retinal sensitivities of early AMD patients measured by 
multifocal electroretinography and microperimetry after 
48  weeks of supplementation with L alone or L and Z 
[79]. Akuffo et al. compared the impact of sustained sup-
plementation using different carotenoid formulations on 
MPOD and visual function (CS and VA) in early AMD. 
After 2 years of follow up, MP augmentation was supe-
rior in the groups receiving the 3 macular carotenoids 
and after 3  years, all groups had significant improve-
ments in CS. No significant changes in VA or progression 
to advanced AMD were observed. These findings suggest 
that adding a higher proportion of MZ leads to a panpro-
file augmentation in MPOD values and improvements in 
CS, indicating that the inclusion of MZ may confer ben-
efits for the treatment of early AMD [22, 80].
Role of lutein and zeaxanthin in other retinal 
diseases
The encouraging results described above have led to sub-
sequent investigations into the role of antioxidants in 
other diseases, including diabetic retinopathy (DR) and 
retinopathy of prematurity (ROP). Retinal ischemia can 
lead to neovascularization, hemorrhage and blindness. 
Oxidative stress plays a role in the pathogenesis of both 
conditions, and earlier evidence suggests that antioxidant 
supplementation may prevent disease progression [81].
ROP is a disease that can cause blindness in very low 
birthweight infants. The incidence of ROP is closely cor-
related with weight and gestational age at birth. Despite 
current therapies, ROP continues to be a highly debili-
tating disease. Oxygen has been well characterized with 
regard to its key role in retinal neoangiogenesis. Low 
or high levels of oxygen regulate the normal or abnor-
mal production of hypoxia-inducible factor-1(HIF-1) 
and vascular endothelial growth factors, which are the 
predominant regulators of retinal angiogenesis [82]. 
The relatively avascular retina then becomes hypoxic 
with increasing metabolic demand, which initiates the 
expression of proangiogenic factors. This stimulates 
aberrant angiogenesis, leading to intravitreal neovascu-
larization and its complications [82, 83]. Also, there is 
an imbalance between the generation and sequestration 
of reactive oxygen species, and the developing retina in 
premature infants is particularly susceptible to oxida-
tive damage for several reasons. The high proportion of 
long chain poly-unsaturated fatty acids makes the retina 
susceptible to lipid peroxidation, which can damage the 
tissue. In addition, preterm infants have reduced lev-
els of antioxidants compared to full-term infants, since 
they are often produced or accumulated later in gesta-
tion. Hence, in preterm infants, the endogenous antioxi-
dant system is overwhelmed, leading to a pro-oxidative 
state, capable of causing irreversible damage to various 
cell structures [84]. Antioxidants can protect retinal cells 
from oxidative damage and have been shown to inhibit 
microvascular degeneration in animal models of ROP 
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[85, 86]. A very recent study demonstrated that Z signifi-
cantly inhibited the expression of VEGF and accumula-
tion of HIF-1α protein caused by hypoxia in a primary 
culture of human retinal pigment epithelium cells [87]. 
Moreover, during fetal development, L is the dominant 
retinal carotenoid, and Z and MZ slowly accumulate 
with time [2]. Also, the presence of L in the umbilical 
cord at birth indicates that there is placental transfer 
with concentrations peaking in the third trimester [88]. 
The relative deficit of antioxidants in preterm infants 
and the growing evidence from animal studies suggest a 
possible role for antioxidant supplementation in the pre-
vention of ROP progression.
A randomized controlled trial of 150 newborns dem-
onstrated that neonatal supplementation of L in the first 
hours of life increased biological antioxidant potential 
and reduced levels of total hydroperoxide [89]. Four ran-
domized controlled trials investigated the relationship 
between xanthophylls and ROP [90–93]. L was the pri-
mary xanthophyll used in the supplementation trials due 
to its predominance in the infant retina. Two multicenter 
placebo-controlled randomized clinical trials study-
ing ROP prevention supplemented preterm infants with 
L/Z via oral feeds of maternal milk, donor human milk, 
or preterm formula [90, 91]. The studies could not find 
any significant differences in ROP incidence. In addition, 
while not statistically significant, supplemented subjects 
with ROP showed a 50  % decrease in progression from 
early to threshold ROP stages [91]. A third clinical trial 
investigated the effect of weight-base dosing, since AMD 
trials have suggested better outcomes with higher carot-
enoid doses. This trial did not show a difference in ROP 
incidence with weight-based doses, but the study was 
limited by small sample size [92]. The fourth multicenter 
randomized controlled trial compared plasma carotenoid 
levels in preterm infants fed formula with and without 
L, lycopene, and β-carotene to carotenoid levels in full-
term infants fed human milk. The incidence of ROP was 
similar between the premature formula-fed groups, but 
the supplemented group had less progression to severe 
stages versus the control group. The supplemented group 
also had similar plasma L levels compared to full-term 
infants fed human milk. The study also compared L lev-
els with photoreceptor activity and found that normal 
plasma L levels at 50 weeks of age correlated with satu-
rated response amplitude in rod photoreceptors and rod 
photoreceptor sensitivity [93]. The authors concluded 
that carotenoid supplementation may decrease inflam-
mation, and their results pointed to the protective effects 
of L on preterm retina health and maturation. To date no 
clinical trials have specifically tested the hypothesis that 
L affects ROP outcomes. While future supplementation 
trials monitoring long-term outcomes in ROP would be 
crucial, current evidence may suggest a role for carote-
noid supplementation in the prevention of ROP and nor-
mal photoreceptor development in preterm infants.
In DR, prolonged hyperglycemia causes oxidative stress 
via several different pathways [15, 94]. Evidence from ani-
mal models suggests that L and Z can block the pathways 
leading to oxidative stress by quenching oxygen radicals, 
therefore preserving retinal function and preventing the 
development of DR [95, 96]. Animal studies have found 
that neuroprotective activities of L prevent neuronal loss 
in diabetic retinas [97, 98]. While a number of studies 
have examined the role of carotenoids in the develop-
ment of diabetes mellitus (DM), there are a limited num-
ber of studies examining their role in the development of 
DR. A serum analysis of patients with type 2 DM dem-
onstrated that patients with a higher concentration of 
L, Z, and lycopene compared to α-carotene, β-carotene 
and β-cryptoxanthin had a 66  % reduction in the risk 
of DR after adjusting for confounding variables [99]. A 
study published by Lima et al. demonstrated that diabetic 
patients had significantly lower levels of MPOD when 
compared to age-matched controls. In comparing the 
diabetic patients, those with retinopathy had even lower 
MPOD than subjects without, and those levels correlated 
with glycosylated hemoglobin [100]. Another study pub-
lished by Hu et  al. found that daily supplementation of 
non-proliferative DR patients with L/Z increased MPOD 
and improved VA, CS and macular edema when com-
pared to placebo [101]. Evidence supporting the role of 
MP in the prevention and treatment of DR is currently 
limited, but animal models and some human supple-
mentation trials suggest that there is a role for L and Z in 
reducing oxidative damage and possibly preventing dis-
ease progression.
Conclusions
MP has been extensively studied during the past dec-
ades. Epidemiological studies have revealed that low MP 
levels are associated with higher risk of AMD. Several 
large observational studies demonstrated that high die-
tary intake and higher serum levels of L and Z are asso-
ciated with a lower risk of AMD, especially late AMD. 
Randomized controlled clinical trials have revealed that 
supplementation of L and Z increases MPOD, improves 
visual function and decreases the risk of progression to 
late AMD, especially neovascular AMD. While the last 
two decades of research have provided many insights into 
the role of MP and other antioxidants in AMD, future 
research studies investigating the optimal antioxidant 
supplement dose, the role of early supplementation, the 
relationship between MPOD as a risk factor for disease 
onset and progression, and the impact of genetic risk 
factors are necessary to better understand the disease 
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process and provide more therapeutic options to patients 
with AMD. Finally, current studies on the preventive 
and therapeutic effects of L and Z on ROP, DR and cata-
ract have yielded varied results. Further investigations 
are necessary to fully understand the role of MP in the 
prevention and treatment of eye diseases such as AMD, 
ROP, DR, and cataract.
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